Measurement of bone mineral density by dual X-ray absorptiometry in Paget's disease before and after pamidronate treatment.
Third-generation bisphosphonates are now currently used in the treatment of Paget's disease of bone. Dual X-ray absorptiometry may make it possible to quantify the action of these bisphosphonates on bone mineral density (BMD) in pagetic and nonpagetic bone. We used Lunar DPX, a total-body software program (automatic analysis and/or manual windows according to the site and bilateral or unilateral pagetic involvement) to study BMD in 28 patients (18 men, 10 women, mean age 69.8 years) with Paget's disease before and 6 months after infusions of 60 mg (alkaline phosphatase <350 IU) or 120 mg (ALP >350 IU) of pamidronate. Before treatment, in the 28 patients, the BMD of trabecular pagetic bone was 25% higher than that of nonpagetic bone; in cortical pagetic bone the BMD was 35% higher. After treatment, the BMD of trabecular pagetic bone increased by only 1.17%. the BMD of cortical pagetic bone increased by 1.37% whereas nonpagetic cortical bone lost 0.84%, independently of the levels of parathyroid hormone or the administration of calcium and vitamin D.
Laroche
M
M
Service de Rhumatologie, CHU Rangueil, 1 avenue Jean-Poulhès, F-31403 Cedex 4, Toulouse, France.
Delpech
B
B
Bernard
J
J
Constantin
A
A
Mazières
B
B
D015502:Absorptiometry, Photon; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D015519:Bone Density; D001842:Bone and Bones / Q000187:drug effects* / Q000473:pathology; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000188:drug therapy* / Q000473:pathology; D000077268:Pamidronate
D000893:Anti-Inflammatory Agents; D004164:Diphosphonates; D000077268:Pamidronate